Stock listing
Frankfurt:PMRA Pharma Mar SA Aktie
German listing (Frankfurt) of Pharma Mar SA · home listing BME:PHM
Follow Pharma Mar SA into a list and get an email when it puts out news.
Share price · FWB:PMRA
€58.35 EUR -3.85 (-6.2%)
Close on Nov 20, 2026
- Day range
- €58.35 – €58.35 EURNov 20, 2026
- Market cap
- €1.01B EURAt the close on Nov 20, 2026 · price × 17.26M shares outstanding
- 52-week range
- €58.35 – €106.02 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €2,871 EURMedian day 0 shares · 51 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| BME:PHM · Home | €57.80 EUR | -4.25 (-6.8%) | 99,554 | €58.60 | €58.60 | €57.15 | €62.05 | Close on Nov 20, 2026 |
| OTC:PHMMF | $66.95 USD | -5.592 (-7.7%) | 100 | $66.95 | $66.95 | $66.95 | $72.54 | Close on Nov 18, 2026 |
| Frankfurt:PMRA | €58.35 EUR | -3.85 (-6.2%) | — | €58.35 | €58.35 | €58.35 | €62.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:PMRA · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €65.07 | -2.797 | -4.1% | €65.07 | €65.07 | €65.07 | 0 | |
| €67.87 | +4.004 | +6.3% | €67.87 | €67.87 | €67.87 | 808 | |
| €63.86 | -0.434 | -0.7% | €63.86 | €63.86 | €63.86 | 808 | |
| €64.30 | -2.84 | -4.2% | €64.39 | €64.41 | €64.30 | 0 | |
| €67.14 | -2.268 | -3.3% | €67.14 | €67.14 | €67.14 | 0 | |
| €69.41 | +0.526 | +0.8% | €69.41 | €69.41 | €69.41 | 238 | |
| €68.88 | +0.438 | +0.6% | €68.88 | €68.88 | €68.88 | 294 | |
| €68.44 | +0.96 | +1.4% | €68.44 | €68.44 | €68.44 | 254 | |
| €67.48 | -1.662 | -2.4% | €67.48 | €67.48 | €67.48 | 0 | |
| €69.14 | -1.309 | -1.9% | €69.14 | €69.14 | €69.14 | 0 | |
| €70.45 | +1.202 | +1.7% | €70.45 | €70.45 | €70.45 | 0 | |
| €69.25 | +0.502 | +0.7% | €69.25 | €69.25 | €69.25 | 0 | |
| €68.75 | +1.389 | +2.1% | €68.75 | €68.75 | €68.75 | 0 | |
| €67.36 | +0.25 | +0.4% | €67.36 | €67.36 | €67.36 | 0 | |
| €67.11 | -1.214 | -1.8% | €67.11 | €67.11 | €67.11 | 0 | |
| €68.32 | +1.669 | +2.5% | €68.32 | €68.32 | €68.32 | 0 | |
| €66.65 | +0.158 | +0.2% | €66.65 | €66.65 | €66.65 | 0 | |
| €66.50 | -1.591 | -2.3% | €66.50 | €66.50 | €66.50 | 0 | |
| €68.09 | -1.684 | -2.4% | €68.09 | €68.09 | €68.09 | 0 | |
| €69.77 | +0.491 | +0.7% | €69.77 | €69.77 | €69.77 | 0 | |
| €69.28 | +0.158 | +0.2% | €69.28 | €69.28 | €69.28 | 0 | |
| €69.12 | -0.72 | -1.0% | €69.12 | €69.12 | €69.12 | 0 | |
| €69.84 | +0.714 | +1.0% | €69.84 | €69.84 | €69.84 | 0 | |
| €69.13 | -1.946 | -2.7% | €69.13 | €69.13 | €69.13 | 0 | |
| €71.07 | +0.65 | +0.9% | €71.07 | €71.07 | €71.07 | 0 | |
| €70.42 | -2.352 | -3.2% | €70.42 | €70.42 | €70.42 | 0 | |
| €72.78 | +0.239 | +0.3% | €72.78 | €72.78 | €72.78 | 0 | |
| €72.54 | -0.87 | -1.2% | €72.54 | €72.54 | €72.54 | 0 | |
| €73.41 | -0.284 | -0.4% | €73.41 | €73.41 | €73.41 | 0 | |
| €73.69 | -0.245 | -0.3% | €73.69 | €73.69 | €73.69 | 0 | |
| €73.94 | +1.172 | +1.6% | €73.94 | €73.94 | €73.94 | 0 | |
| €72.76 | -1.643 | -2.2% | €72.76 | €72.76 | €72.76 | 0 | |
| €74.41 | +0.764 | +1.0% | €74.41 | €74.41 | €74.41 | 0 | |
| €73.64 | +0.024 | 0.0% | €73.64 | €73.64 | €73.64 | 0 | |
| €73.62 | -1.259 | -1.7% | €73.62 | €73.62 | €73.62 | 0 | |
| €74.88 | -2.184 | -2.8% | €74.88 | €74.88 | €74.88 | 0 | |
| €77.06 | +1.241 | +1.6% | €77.06 | €77.06 | €77.06 | 0 | |
| €75.82 | -0.431 | -0.6% | €75.82 | €75.82 | €75.82 | 0 | |
| €76.25 | -0.174 | -0.2% | €76.25 | €76.25 | €76.25 | 0 | |
| €76.43 | -0.553 | -0.7% | €76.43 | €76.43 | €76.43 | 0 | |
| €76.98 | -1.357 | -1.7% | €76.99 | €77.42 | €76.10 | 40 | |
| €78.34 | -0.468 | -0.6% | €78.34 | €78.34 | €78.34 | 0 | |
| €78.80 | -2.664 | -3.3% | €78.80 | €78.80 | €78.80 | 0 | |
| €81.47 | -1.352 | -1.6% | €81.47 | €81.47 | €81.47 | 0 | |
| €82.82 | -0.384 | -0.5% | €82.82 | €82.82 | €82.82 | 0 | |
| €83.20 | +1.028 | +1.3% | €83.20 | €83.20 | €83.20 | 0 | |
| €82.18 | +0.401 | +0.5% | €82.18 | €82.18 | €82.18 | 0 | |
| €81.78 | +0.823 | +1.0% | €81.78 | €81.78 | €81.78 | 0 | |
| €80.95 | -1.496 | -1.8% | €80.95 | €80.95 | €80.95 | 0 | |
| €82.45 | -0.626 | -0.8% | €82.45 | €82.45 | €82.45 | 0 | |
| €83.07 | -0.732 | -0.9% | €83.07 | €83.07 | €83.07 | 0 | |
| €83.81 | +0.58 | +0.7% | €83.81 | €83.81 | €83.81 | 0 | |
| €83.23 | +1.339 | +1.6% | €83.23 | €83.23 | €83.23 | 0 | |
| €81.89 | -2.384 | -2.8% | €81.89 | €81.89 | €81.89 | 0 | |
| €84.27 | +1.299 | +1.6% | €84.27 | €84.27 | €84.27 | 0 | |
| €82.97 | +1.86 | +2.3% | €82.97 | €82.97 | €82.97 | 0 | |
| €81.11 | +0.26 | +0.3% | €81.11 | €81.11 | €81.11 | 0 |
Splits
1 split · FWB:PMRA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation |
- Ticker
- Frankfurt:PMRA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Mar 13, 2026
Pharma Mar: Consolidated Financial Statements and Consolidated Directors' Report (Consolidated Financial Statements and Consolidated Directors)
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 25 slides
Latest news
Pharma Mar: Consolidated Financial Statements and Consolidated Directors' Report (Consolidated Financial Statements and Consolidated Directors)
Mar 13, 2026
Closed €78.58 (-2.3%) on Mar 13, 2026
Press Release (PR PhM Results FY2025 final 1)
Feb 27, 2026
Closed €78.06 (+2.3%) on Feb 27, 2026
Pharma Mar SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 7 in all · newest Mar 13, 2026 · oldest 2017
- Calls
- 2 calls with a replay · 2 with a transcript · latest Oct 27, 2023
- Decks
- 33 decks · latest September 2026
Where Pharma Mar SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| BME:PHM · Home listing | Madrid | Spain | EUR |
| gettex:PMRA | gettex | Germany | EUR |
| VIE:PHM | Vienna | Austria | EUR |
| OTC:PHMMF | OTC | United States | USD |
| LS Exchange:A2P9YT | LS Exchange | Germany | EUR |
| Tradegate:PMRA | Tradegate | Germany | EUR |
| LSIN:0RC6 | LSIN | United Kingdom | EUR |
| Lang & Schwarz:A2P9YT | Lang & Schwarz | Germany | EUR |
| Aquis:PHME | Aquis | United Kingdom | EUR |
| Dusseldorf:PMRA | Dusseldorf | Germany | EUR |
| Stuttgart:PMRA | Stuttgart | Germany | EUR |
| Aquis:PHME | Aquis | United Kingdom | EUR |
| Turquoise:PHME | Turquoise | United Kingdom | EUR |
| Frankfurt:PMRA · This page | Frankfurt | Germany | EUR |
| Hamburg:PMRA | Hamburg | Germany | EUR |
| Munich:PMRA | Munich | Germany | EUR |
Valuation
P/E 14.6× against a median of 102×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- €891.6M EUR
- P/E
- 14.6×
- EV/sales
- 3.8×
- EV/EBITDA
- 16.6×
- Price/book
- 4.2×
- Gross margin
- 90.7%
- Operating margin
- 19.1%
- Net margin
- 28.8%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pharma Mar SA · BME:PHM | US$1.10B | US$978.5M | 14.6× | 3.8× | 16.6× | 4.2× | 28.8% | 0.3× | n/a |
| CStone Pharmaceuticals · HKEX:2616 | US$1.16B | US$974.9M | n/a | 24.1× | n/a | 6.0× | −162.1% | 0.3× | n/a |
| Structure Therapeutics, Inc. · NASDAQ:GPCR | US$1.15B | −US$82.92M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.38 |
| COMPASS Pathways Plc · NASDAQ:CMPS | US$1.14B | US$747.8M | n/a | n/a | n/a | 8.0× | n/a | 0.4× | 1.65 |
| Ascentage Pharma Group International · HKEX:6855 | US$1.11B | US$1.14B | n/a | 13.7× | n/a | 13.4× | −216.5% | 3.8× | n/a |
| Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321 | US$1.10B | US$1.10B | 102× | 6.8× | n/a | 2.9× | 6.6% | 0.5× | n/a |
| Alpha Tau Medical Ltd · NASDAQ:DRTS | US$1.09B | US$1.00B | n/a | n/a | n/a | 55.3× | n/a | 0.8× | 1.89 |
| Kardigan, Inc. · NASDAQ:KARD | US$1.08B | US$621.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| PYC Therapeutics Limited · ASX:PYC | US$1.07B | US$775.8M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Jade Biosciences, Inc. · NASDAQ:JBIO | US$1.06B | US$583.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.14 |
| MedinCell SA · EURONEXT:MEDCL | US$1.05B | US$1.02B | n/a | 38.4× | n/a | 313× | −128.9% | 18.7× | n/a |
| Median of the others | US$1.09B | US$875.4M | 102× | 18.9× | 4.4× | −145.5% | 0.3× | 1.52 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 98.94 EUR · Analysts' mean
- EPS, year to Dec 2026
- 2.08 · 6 analysts
- Revenue, year to Dec 2026
- 220.3M · 5 analysts
Team and board
| Officer | Role |
|---|---|
| Miriam Collados Gordo | Corporate Communications Manager |
| Natalia Amo | Capital Markets & Investor Relations |
| Luis Mora | Managing Director |
Events
- Next results
- Feb 25, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Pharma Mar (Madrid:PHM) Q3 2023 Earnings Call | Fri, Oct 27, 2023 | Replay |
| Pharma Mar (Madrid:PHM) Q4 2022 Earnings Call | Mon, May 01, 2023 | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · After close | −2.5% |
| Q2 2026 | Jul 29, 2026 · After close | −1.1% |
| Q1 2026 | Apr 27, 2026 · After close | +1.9% |
| Q4 2025 | Mar 5, 2026 · After close | +0.3% |
| Q3 2025 | Oct 30, 2025 · After close | −1.4% |
| Q2 2025 | Jul 30, 2025 · After close | −0.6% |
| Q1 2025 | Apr 24, 2025 · After close | −10.3% |
| Q4 2024 | Feb 26, 2025 · After close | −0.3% |
| Q3 2024 | Oct 29, 2024 · After close | −0.1% |
| Q2 2024 | Jul 30, 2024 · After close | −0.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 23, 2024 · After close | +3.0% |
| Q4 2023 | Feb 28, 2024 · After close | −3.9% |
| Q3 2023 | Oct 26, 2023 · After close | +3.2% |
| Q2 2023 | Jul 27, 2023 · After close | −0.8% |
| Q1 2023 | Apr 27, 2023 · After close | +2.3% |
| Q4 2022 | Feb 28, 2023 · After close | −2.4% |
| Q3 2022 | Oct 26, 2022 · After close | −0.9% |
| Q2 2022 | Jul 28, 2022 · After close | −5.5% |
| Q1 2022 | Apr 28, 2022 · Before open | +0.2% |
| Q4 2021 | Feb 28, 2022 · Before open | +6.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 25 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 24 slides | August 2026 |
| Investor Presentation (July 2026) | Investor deck | 24 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 25 slides | June 2026 |
| Investor Presentation (May 2026) | Investor deck | 25 slides | May 2026 |
| Investor Presentation (November 2025) | Investor deck | 26 slides | November 2025 |
| Investor Presentation (October 2025) | Investor deck | 26 slides | October 2025 |
| Investor Presentation (July 2025) | Investor deck | 25 slides | July 2025 |
| Investor Presentation (February 2025) | Investor deck | 23 slides | February 2025 |
| Investor Presentation (April 2024) | Investor deck | 29 slides | April 2024 |
All 33 decks
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 221.4M | 174.9M | 158.2M | 196.3M | 229.8M | 270.0M | 85.8M | 162.2M | 179.3M | 180.9M |
| Cost of revenue | 12.3M | 8.18M | 9.61M | 13.6M | 16.4M | 13.7M | 5.23M | 35.9M | 45.7M | 44.0M |
| Gross profit | 209.1M | 166.7M | 148.5M | 182.7M | 213.4M | 256.2M | 80.6M | 126.3M | 133.7M | 137.0M |
| Research and development | 95.2M | 103.5M | 99.3M | 83.4M | 72.2M | 53.8M | 50.6M | 74.0M | 78.5M | 78.4M |
| Selling, general and administrative | 2.34M | 2.85M | 18.3M | 19.0M | 17.4M | 13.5M | 13.9M | 17.4M | 20.7M | 20.3M |
| Operating income | 60.7M | 6.47M | -3.83M | 44.1M | 92.4M | 155.9M | -17.5M | -14.1M | -17.7M | -18.7M |
| Depreciation and amortization | 8.02M | 6.77M | 5.76M | 5.90M | 5.58M | 7.21M | 6.05M | 6.38M | 7.06M | 7.24M |
| EBITDA | 68.7M | 13.2M | 1.93M | 50.0M | 98.0M | 163.2M | -11.4M | -7.70M | -10.6M | -11.5M |
| Interest expense | 6.51M | 8.53M | 9.43M | 11.3M | 7.68M | 3.12M | 3.89M | 4.14M | 5.12M | 5.21M |
| Income before tax | 59.7M | 12.0M | -3.62M | 43.8M | 95.1M | 145.6M | -21.7M | -18.7M | -22.9M | -24.7M |
| Income tax | -15.3M | -14.1M | -4.76M | -5.57M | 2.27M | 8.34M | -12.5M | -2.50M | 3.90M | -592.0K |
| Net income | 75.0M | 26.1M | 1.14M | 49.4M | 92.9M | 137.3M | -9.18M | -5.54M | -26.7M | -24.1M |
| Earnings per share, basic | 4.30 | 1.49 | 0.06 | 2.73 | 5.14 | 7.49 | -0.50 | -0.30 | -1.45 | -1.31 |
| Earnings per share, diluted | 4.30 | 1.49 | 0.06 | 2.73 | 5.13 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.8M | 63.2M | 60.0M | 149.8M | 113.3M | 96.2M | 17.6M | 22.7M | 24.1M | 14.3M |
| Short-term investments | 149.4M | 91.3M | 102.5M | 32.6M | 88.5M | 99.3M | 3.26M | 4.13M | 7.67M | 18.1M |
| Receivables | 39.4M | 34.7M | 27.6M | 29.3M | 50.9M | 26.7M | 13.2M | 23.5M | 31.4M | 62.6M |
| Inventory | 54.1M | 52.0M | 39.3M | 27.7M | 10.5M | 11.9M | 8.90M | 20.6M | 23.9M | 22.2M |
| Current assets | 283.4M | 250.2M | 252.6M | 275.2M | 295.2M | 245.7M | 50.0M | 75.1M | 93.2M | 121.0M |
| Property, plant and equipment | 57.4M | 55.9M | 43.9M | 31.2M | 27.0M | 24.7M | 25.6M | 25.5M | 30.6M | 29.0M |
| Goodwill | 0 | 2.55M | 2.55M | 2.55M | ||||||
| Total assets | 395.1M | 349.6M | 340.5M | 393.3M | 368.4M | 330.3M | 124.7M | 157.7M | 187.7M | 221.1M |
| Accounts payable | 54.3M | 51.6M | 40.3M | 30.0M | 29.3M | 21.0M | 16.5M | 31.2M | 35.8M | 36.7M |
| Current liabilities | 93.9M | 82.7M | 95.9M | 97.3M | 86.3M | 94.9M | 60.4M | 72.4M | 83.1M | 87.2M |
| Long-term debt | 35.6M | 39.9M | 27.0M | 25.9M | 33.4M | 37.7M | 53.1M | 64.9M | 73.6M | 67.6M |
| Total debt | 38.6M | 43.2M | 30.4M | 39.0M | 49.3M | 56.7M | 86.1M | 93.4M | 100.0M | 95.5M |
| Total liabilities | 143.2M | 141.3M | 147.1M | 170.3M | 190.5M | 227.5M | 117.2M | 140.2M | 164.7M | 172.6M |
| Shareholders' equity | 251.8M | 208.4M | 193.4M | 223.0M | 177.9M | 102.7M | 11.4M | 21.4M | 26.9M | 52.4M |
| Shares outstanding | 17.2M | 17.6M | 17.9M | 18.1M | 18.1M | 18.3M | 18.4M | 18.4M | 18.4M | 18.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 53.1M | 6.03M | -13.4M | 38.3M | 25.7M | 278.9M | -26.1M | -16.3M | -1.46M | -8.41M |
| Capital spending | -6.46M | -15.0M | -14.8M | -8.85M | -7.80M | -3.00M | -3.91M | -2.38M | -4.67M | -6.09M |
| Free cash flow | 46.7M | -8.99M | -28.3M | 29.5M | 17.9M | 275.9M | -30.0M | -18.7M | -6.12M | -14.5M |
| Cash from investing | -60.8M | 1.03M | -43.0M | 10.9M | 18.5M | -119.0M | 32.1M | 22.3M | 6.00M | 13.8M |
| Cash from financing | -36.5M | -5.35M | -32.1M | -13.4M | -27.4M | -73.8M | -11.0M | -7.26M | 5.26M | 1.30M |
| Dividends paid | -13.9M | -11.4M | -11.7M | -11.8M | -10.9M | -8.82M | -8.82M | -6.92M | -19.9M | -20.1M |
| Share buybacks | -34.1M | -18.6M | -37.9M | -50.2M | -40.7M | -63.7M | -7.48M | -3.45M | -6.19M | -4.17M |
| Change in cash | -45.4M | 3.21M | -89.8M | 36.5M | 17.1M | 78.6M | -5.11M | -1.34M | 9.80M | 6.66M |
Cap table
Built by 6ix from Pharma Mar SA’s releases
- Common shares
- 17,263,774
- Fully diluted
- 17,263,774
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 17,263,774 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 17,263,774 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Miriam Collados Gordo | Corporate Communications Manager · Since at least Feb 27, 2026 |
| Natalia Amo | Capital Markets & Investor Relations · Since at least Feb 27, 2026 |
Log in to ask 6ix AI your own questions about Pharma Mar SA.